Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
ESMO Open|November 18, 2025
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50A De Giglio, L Zullo, A Di Federico, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARDJ W Riess, H A Yu, X Le, et al.
ESMO Open|January 21, 2026
Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancerE J van Dijk, M M Smeenk, F Bensch, et al.
ESMO Open|November 5, 2024
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapyV D de Jager, P Plomp, M S Paats, et al.
Pageof 2